1.1Costimulation on a bead
Polymer beads carry immobilized antibodies to CD3 and CD28. The bead surface clusters both receptors on responsive T cells and supplies activation and costimulation during ex vivo culture.
Generated automatically. Not reviewed by a person. Not legal advice or an opinion.
Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.
Polymer beads carry immobilized antibodies to CD3 and CD28. The bead surface clusters both receptors on responsive T cells and supplies activation and costimulation during ex vivo culture.
A shallow microwell confines the two cells, and a monospecific CD40 agonist supplies the activation signal to the antigen presenting cell. Surface peptide–major histocompatibility complexes and native costimulatory ligands provide signals to the effector cell during contact.
The culture uses T cells with native receptors that recognize a selected peptide bound to a major histocompatibility complex. Peptide-loaded presenting cells stimulate those T cells, and the associated CD3 complex transmits the activation signal.
A separate aliquot of target-reactive T cells is expanded and tested for target-cell killing. The functional aliquot supplies the cytotoxic activity when transferred into the assay or culture.
Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.
A veterinary oncology assay combines canine tumor organoids, dendritic cells, and tumor-reactive lymphocytes from the same animal. One binding arm recognizes canine CD40 on dendritic cells, and the other recognizes canine CD8 on the lymphocytes. Time-lapse imaging tracks lymphocyte contacts with organoids, and a fluorescent viability stain measures tumor cell killing in wells with and without the bispecific polypeptide.
A single-domain antibody fragment that recognizes CD40 replaces the antigen-presenting-cell binding arm. A flexible glycine-serine linker joins this fragment to a single-chain variable fragment that recognizes an extracellular epitope tag on the effector cell. Both fragments form one soluble polypeptide, and dual binding is assessed by measuring effector cell and antigen-presenting cell conjugates by flow cytometry.
Two single-chain variable fragments replace the paired arms and constant-region scaffold of an antibody-format bispecific. A flexible peptide linker joins an antigen-presenting-cell-specific fragment to an effector-cell-specific fragment in a single soluble chain. The two fragments bind their respective cell-surface antigens, and fluorescence microscopy measures cell conjugate formation against a control chain with one binding fragment inactivated.
A 96-well plate holds 100 microliters per well, with 10,000 effector cells and 5,000 antigen-presenting cells in each well. Replicate wells receive the same bispecific polypeptide concentration for 1, 4, or 24 hours. At the end of each exposure, the cells are washed, exposed to antigen-bearing tumor target cells, and assayed for target cell killing after a fixed 6-hour interval.
A microfluidic perfusion chip contains a collagen gel chamber with tumor organoids, antigen-presenting cells, and effector cells. An adjacent fluid channel delivers the soluble bispecific polypeptide, which diffuses into the chamber and binds surface antigens on the two immune cell populations. Optical imaging tracks immune cell contacts and organoid viability, and timed outlet samples provide soluble cytokine measurements.
A liquid handler dispenses antigen-presenting cells, effector cells, and serial dilutions of the bispecific polypeptide into a multiwell plate. An automated microscope images the two cell populations using distinct fluorescent labels, and image analysis measures the fraction of effector cells in contact with antigen-presenting cells. Software selects the lowest tested concentration that meets a preset contact threshold and transfers cells from replicate wells at that concentration to a separate tumor target killing assay.
A single polypeptide contains two antibody variable-domain fragments joined by a flexible peptide linker. One fragment binds CD40 on a dendritic cell, and the other binds an exposed peptide tag on the effector-cell receptor.
The receptor contains an extracellular antibody fragment for target recognition and an exposed peptide tag for bispecific binding. A transmembrane segment anchors the receptor, and intracellular CD28 and CD3 zeta domains transmit activation signals.
Exposed effector cells are washed and challenged with fluorescently labeled antigen-bearing targets at a fixed effector-to-target ratio. Loss of viable targets relative to a matched untreated exhausted-cell culture measures recovery of cytotoxic activity.
Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.
In further aspects, the immune effector cells of the cell culture (comprising an engineered APC of the embodiments) express a chimeric T-cell receptor (CAR) that binds to an epitope of the target antigen in complex with the HLA expressed in the engineered APCs. The CAR may comprise antibody variable domains that bind to an epitope of the target antigen in complex with the HLA expressed in the APCs.A · US 2017/0333480 A1 · ¶ 33
In further aspects, the immune effector cells of the cell culture (comprising an engineered APC of the embodiments) express a chimeric T-cell receptor (CAR) that binds to an epitope of the target antigen in complex with the HLA expressed in the engineered APCs. The CAR may comprise antibody variable domains that bind to an epitope of the target antigen in complex with the HLA expressed in the APCs.B · US 2022/0072041 A1 · ¶ 34
In some embodiments, the chimeric antigen receptor comprises: a) an intracellular signaling domain, b) a transmembrane domain, and c) an extracellular domain comprising an antigen binding domain.A · US 2017/0333480 A1 · ¶ 116
In some embodiments, the chimeric antigen receptor comprises: a) an intracellular signaling domain, b) a transmembrane domain, and c) an extracellular domain comprising an antigen binding domain.B · US 2022/0072041 A1 · ¶ 117
The intracellular signaling domain of the chimeric antigen receptor of the embodiments is responsible for activation of at least one of the normal effector functions of the immune cell engineered to express a chimeric antigen receptor.A · US 2017/0333480 A1 · ¶ 132
The intracellular signaling domain of the chimeric antigen receptor of the embodiments is responsible for activation of at least one of the normal effector functions of the immune cell engineered to express a chimeric antigen receptor.B · US 2022/0072041 A1 · ¶ 133
An empty cell means only that no passage was reproduced there.
Such genetic engineering of T cells can be used to redirect the specificity of the cells and to provide therapeutic compositions having antigen-targeted cytotoxic activity.A · US 2017/0333480 A1 · ¶ 4
There remains a need however, for improved T-cell and CAR constructs that allow for control of in vivo persistence.A · US 2017/0333480 A1 · ¶ 4
Such genetic engineering of T cells can be used to redirect the specificity of the cells and to provide therapeutic compositions having antigen-targeted cytotoxic activity.B · US 2022/0072041 A1 · ¶ 5
There remains a need however, for improved T-cell and CAR constructs that allow for control of in vivo persistence.B · US 2022/0072041 A1 · ¶ 5
patent.fyi, US 2026/0355315 A1, claim 1, first published 2026-11-19T10:32:39-05:00, https://patent.fyi/US20260355315/, SHA-256 f24dbab8487432a40ae7f44391587bd2a073606f16c4b01935f548eed3bba76d